Concetta Laliscia1, Maria Grazia Fabrini2, Durim Delishaj2, Gabriele Coraggio2, Riccardo Morganti3, Roberta Tana4, Fabiola Paiar2, Angiolo Gadducci4. 1. Division of Radiation Oncology, Department of Translation Medicine, University of Pisa, Pisa, Italy c.laliscia@ao-pisa.toscana.it. 2. Division of Radiation Oncology, Department of Translation Medicine, University of Pisa, Pisa, Italy. 3. Section of Statistics, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy. 4. Division of Gynecology and Obstetrics, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Abstract
AIM: To assess the outcome of 35 patients with vaginal carcinoma treated with different radiotherapy modalities. MATERIALS AND METHODS: Thirty-one patients received external-beam irradiation (EBRT) to the entire vagina, para-vaginal area and pelvic nodes (total dose=45-50.4 Gy). Concomitant chemotherapy was used in 22 patients. Nineteen patients received additional 15-25 Gy high-dose-rate brachytherapy (BT) boost and eight received additional EBRT boost to the primary tumor site. Four women received exclusive 30-40 Gy high-dose-rate BT. RESULTS: Median progression-free survival and median overall survival were 22 months and 89 months, respectively. Age <70 years, use of EBRT plus BT, and concomitant chemotherapy were associated with better progression-free (p=0.002, p=0.007, and p=0.02) and overall (p=0.01, p=0.009, p=0.009) survival. CONCLUSION: Concomitant EBRT and chemotherapy followed by BT is the best treatment for vaginal carcinoma. Copyright
AIM: To assess the outcome of 35 patients with vaginal carcinoma treated with different radiotherapy modalities. MATERIALS AND METHODS: Thirty-one patients received external-beam irradiation (EBRT) to the entire vagina, para-vaginal area and pelvic nodes (total dose=45-50.4 Gy). Concomitant chemotherapy was used in 22 patients. Nineteen patients received additional 15-25 Gy high-dose-rate brachytherapy (BT) boost and eight received additional EBRT boost to the primary tumor site. Four women received exclusive 30-40 Gy high-dose-rate BT. RESULTS: Median progression-free survival and median overall survival were 22 months and 89 months, respectively. Age <70 years, use of EBRT plus BT, and concomitant chemotherapy were associated with better progression-free (p=0.002, p=0.007, and p=0.02) and overall (p=0.01, p=0.009, p=0.009) survival. CONCLUSION: Concomitant EBRT and chemotherapy followed by BT is the best treatment for vaginal carcinoma. Copyright
Authors: Sara Guerri; Anna M Perrone; Milly Buwenge; Martina Ferioli; Gabriella Macchia; Luca Tagliaferri; Gabriella Ferrandina; Andrea Galuppi; Angela D Andrulli; Rezarta Frakulli; Silvia Cammelli; Alessandra Arcelli; Pierandrea De Iaco; Alessio G Morganti Journal: Oncologist Date: 2018-08-23